Thank you for your interest in PPMI! We agree you completely, and are currently working on efforts to develop models of synucleinopathy. Please feel free to sign up for our PPMI newsletter for up to date information about the study (http://www.ppmi-info.org/get-email-updates/)
Please feel free to contact us if you have any other questions.
Best,
Vanessa
Vanessa Arnedo Associate Director, Research Partnerships
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON’S RESEARCH
Except for the part that includes my actual email address, that is the entire email that I received from the associate director of research partnerships at the MJFF. Note she is into research partnerships.
While I am at it, There is one other MJFF reference that is important to this topic.
MJFF does not think that the most recent conclusion is supported by the data. MJFF did reserve the right to change their mind, based on future data. So we will see. However, the Exhibit 99.1 of the Dec 27 SEC 8k filing stands.
That statement refers to the MJFF interpretation of the study they helped support of MANF in PD. See the entire Exhibit for more details. Again, while they reserved the right to change their mind, in 18 months, they have chosen not to do so.
by the way, if you want to find an old post, I would recommend that you google it.
Market Data 
Markets 
AI
